Immune checkpoint inhibitors, such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, can unleash T-cell-mediated cytotoxicity against BCSCs, thereby impeding tumor progression. The gene discussed is CTLA4; the disease is neoplasm.